Agios Pharmaceuticals (AGIO) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $45.5 million.
- Agios Pharmaceuticals' Accumulated Expenses fell 299.18% to $45.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $45.5 million, marking a year-over-year decrease of 299.18%. This contributed to the annual value of $45.5 million for FY2025, which is 299.18% down from last year.
- Agios Pharmaceuticals' Accumulated Expenses amounted to $45.5 million in Q4 2025, which was down 299.18% from $37.2 million recorded in Q3 2025.
- In the past 5 years, Agios Pharmaceuticals' Accumulated Expenses ranged from a high of $46.9 million in Q4 2024 and a low of $19.7 million during Q1 2022
- Moreover, its 5-year median value for Accumulated Expenses was $30.4 million (2022), whereas its average is $31.8 million.
- Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 4120.75% in 2021, then soared by 4223.06% in 2023.
- Quarter analysis of 5 years shows Agios Pharmaceuticals' Accumulated Expenses stood at $32.0 million in 2021, then dropped by 5.06% to $30.4 million in 2022, then soared by 42.23% to $43.2 million in 2023, then grew by 8.56% to $46.9 million in 2024, then decreased by 2.99% to $45.5 million in 2025.
- Its last three reported values are $45.5 million in Q4 2025, $37.2 million for Q3 2025, and $35.3 million during Q2 2025.